Liminatus Pharma, Inc.
LIMNW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001971387
No open-market purchases or sales by Liminatus Pharma, Inc. insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $90.1K in total; no superinvestor holds it.
Other share classesLIMN
Q4 2025 vs. Q3 2025
How the institutions holding Liminatus Pharma, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Of which not filed for Q4 2025 | Q4 2025 | Change |
|---|---|---|---|---|
| Holders | 27 | 1 | 25 | −1 |
| Shares | 2.64M | 15.8K | 2.46M | −162.0K (−6.2%) |
| Value | $400.3K | $2.33K | $95.0K | −$303.0K (−76.1%) |
1 institution that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (2)
Institutions that held Liminatus Pharma, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 23,906 | $837 | 0.00% |
| Point72 Asset Management, L.P. | 12,400 | $434 | 0.00% |
Sold out (3)
Institutions that held Liminatus Pharma, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Nomura Holdings Inc | 97,325 | $11.7K |
| Falcon Edge Capital, LP | 89,098 | $10.7K |
| Meteora Capital, LLC | 15,000 | $2.22K |
Not filed for Q4 2025 yet (1)
Institutions that held Liminatus Pharma, Inc. at the end of Q3 2025 and haven't filed a 13F for Q4 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Cubist Systematic Strategies, LLC | 15,778 | $2.33K |